SIG
LUCD icon

Sargent Investment Group’s Lucid Diagnostics LUCD Stock Holding History

Sargent Investment Group’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.5K Buy
65,000
+10,970
+20% +$11.8K 0.01% 275
2026
Q1 		$62.1K Hold
54,030
– – 0.01% 264
2025
Q4 		$58.9K Hold
54,030
– – 0.01% 257
2025
Q3 		$54.6K Hold
54,030
– – 0.01% 119
2025
Q2 		$53.5K Buy
54,030
+10,530
+24% +$13.6K 0.01% 233
2025
Q1 		$64.8K Sell
43,500
-498,000
-92% -$598K 0.01% 228
2024
Q4 		$442K Buy
+541,500
New +$478K 0.07% 142

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Sargent Investment Group's LUCD Position: Q2 2026 in Review

Sargent Investment Group increased its Lucid Diagnostics (LUCD) stake by 20% in Q2 2026, buying an estimated $11.8K and bringing the position to 65,000 shares worth $69.5K. The position accounts for 0.01% of the portfolio, ranked #275.

Sargent Investment Group first reported a position in LUCD in Q4 2024 and has held it in 7 quarters since. The position peaked at $442K in Q4 2024. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Sargent Investment Group held 65,000 shares of Lucid Diagnostics worth $69.5K as of Q2 2026.
  • Sargent Investment Group bought 10,970 Lucid Diagnostics shares in Q2 2026, an estimated $11.8K.
  • Lucid Diagnostics made up 0.01% of Sargent Investment Group's portfolio in Q2 2026, its #275 holding.
  • Sargent Investment Group first reported a position in Lucid Diagnostics in Q4 2024 and has held it in 7 quarters since.
  • Sargent Investment Group's Lucid Diagnostics position peaked at $442K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Sargent Investment Group's 13F filing for Q2 2026, filed 11 Aug 2026.